These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28011979)

  • 1. Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma.
    Lee JY; Song C; Hong BS; Hong JH; Ahn H; Lee JL
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):173-180. PubMed ID: 28011979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience.
    Hanzly M; Aboumohamed A; Yarlagadda N; Creighton T; Digiorgio L; Fredrick A; Rao G; Mehedint D; George S; Attwood K; Kauffman E; Narashima D; Khushalani NI; Pili R; Schwaab T
    Urology; 2014 May; 83(5):1129-34. PubMed ID: 24767525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.
    Yang JC; Topalian SL; Parkinson D; Schwartzentruber DJ; Weber JS; Ettinghausen SE; White DE; Steinberg SM; Cole DJ; Kim HI
    J Clin Oncol; 1994 Aug; 12(8):1572-6. PubMed ID: 8040669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year survival results of subcutaneous low-dose immunotherapy with interleukin-2 alone in metastatic renal cell cancer patients.
    Bordin V; Giani L; Meregalli S; Bukovec R; Vaghi MM; Mandalà M; Paolorossi F; Ardizzoia A; Tancini G; Barni S; Frigerio F; Fumagalli L; Bordoni A; Valsuani G; Di Felice G; Lissoni P
    Urol Int; 2000; 64(1):3-8. PubMed ID: 10782024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.
    Dandamudi UB; Ghebremichael M; Sosman JA; Clark JI; McDermott DF; Atkins MB; Dutcher JP; Urba WJ; Regan MM; Puzanov I; Crocenzi TS; Curti BD; Vaishampayan UN; Crosby NA; Margolin KA; Ernstoff MS
    J Immunother; 2013; 36(9):490-5. PubMed ID: 24145360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
    Koo DH; Park I; Ahn JH; Lee DH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Lee JL
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
    Marincola FM; White DE; Wise AP; Rosenberg SA
    J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
    Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
    Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant subcutaneous interleukin-2 in patients with resected renal cell carcinoma: a pilot study.
    Majhail NS; Wood L; Elson P; Finke J; Olencki T; Bukowski RM
    Clin Genitourin Cancer; 2006 Jun; 5(1):50-6. PubMed ID: 16859579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
    Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: a phase II trial of the National Biotherapy Study Group.
    Dillman RO; Wiemann MC; Bury MJ; Church C; DePriest C
    Cancer Biother Radiopharm; 1997 Feb; 12(1):5-11. PubMed ID: 10851441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma.
    Koulova L; Novik Y; Caliendo G; Wiernik P; Dutcher J
    J Immunother; 2005; 28(6):576-81. PubMed ID: 16224275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.
    Yang JC; Topalian SL; Schwartzentruber DJ; Parkinson DR; Marincola FM; Weber JS; Seipp CA; White DE; Rosenberg SA
    Cancer; 1995 Aug; 76(4):687-94. PubMed ID: 8625167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
    Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients.
    Gitlitz BJ; Hoffman DM; Moldawer N; Belldegrun A; Figlin RA
    Cancer J; 2001; 7(2):112-20. PubMed ID: 11324764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
    Garcia JA; Mekhail T; Elson P; Wood L; Bukowski RM; Dreicer R; Rini BI
    BJU Int; 2012 Jan; 109(1):63-9. PubMed ID: 21244601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
    Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
    Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
    Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
    Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
    Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
    J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.